Clinical and neurobiological factors in the management of treatment refractory attention-deficit hyperactivity disorder

Se Hoon Shim, Hee jung Yoon, Jeongjae Bak, Sang Woo Hahn, Yong Ku Kim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is a highly prevalent mental disorder of childhood, which often continues into adolescence and adulthood. Stimulants such as methylphenidate (MPH) and non-stimulants such as atomoxetine are effective medications for the treatment of ADHD. However, about 30% of patients do not respond to these medications. Pharmacological treatment for ADHD, although highly effective, is associated with marked variabilities in clinical response, optimal dosage needed and tolerability. This article provides an overview of up-to-date knowledge regarding the clinical and neurobiological factors which contribute to and help predict treatment-refractory ADHD. Pharmacogenetic, pharmacogenomics and neuroimaging studies are still controversial with respect to determining the associations between response to medication and genetic factors, thereby resulting in hypotheses that differences in the genetic factors and neuroimaging findings contribute to treatment outcome. Much research on the potential role of genotype in pharmacological effects has focused on the catecholaminergic gene related to executive functions. Many neuroimaging studies have also reported a relationship between treatment response and common patterns of brain structure or activity according to various genetic polymorphisms. When children, adolescents and adults with ADHD do not respond to MPH, we should consider additional pharmacological options, including other classes of psychostimulants, the nonstimulant atomoxetine, bupropion, tricyclic antidepressant, clonidine, guanfacine and lisdexamphetamine. Prudent choice of an appropriate medication and active engagement of children, parents, and teachers in daily management may help to ensure long-term adherence. Therefore, additional research might help to optimize the treatment of children, adolescents and adults with ADHD and to find new options for the treatment of patients who do not respond to stimulants and the other medications. Because these findings should be interpreted cautiously, further studies are needed to elucidate these issues more clearly.

Original languageEnglish
Pages (from-to)237-244
Number of pages8
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume70
DOIs
Publication statusPublished - 2016 Feb 2

Fingerprint

Attention Deficit Disorder with Hyperactivity
Neuroimaging
Methylphenidate
Pharmacology
Therapeutics
Guanfacine
Bupropion
Tricyclic Antidepressive Agents
Pharmacogenetics
Executive Function
Clonidine
Genetic Polymorphisms
Research
Mental Disorders
Parents
Genotype
Brain
Genes

Keywords

  • Atomoxetine
  • Attention deficit hyperactivity disorder
  • Methylphenidate
  • Neuroimaging
  • Pharmacogenetics
  • Treatment response

ASJC Scopus subject areas

  • Pharmacology
  • Biological Psychiatry

Cite this

Clinical and neurobiological factors in the management of treatment refractory attention-deficit hyperactivity disorder. / Shim, Se Hoon; Yoon, Hee jung; Bak, Jeongjae; Hahn, Sang Woo; Kim, Yong Ku.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 70, 02.02.2016, p. 237-244.

Research output: Contribution to journalArticle

@article{0b2bbf32d8e048a3b6d30ba2ca33624b,
title = "Clinical and neurobiological factors in the management of treatment refractory attention-deficit hyperactivity disorder",
abstract = "Attention-deficit/hyperactivity disorder (ADHD) is a highly prevalent mental disorder of childhood, which often continues into adolescence and adulthood. Stimulants such as methylphenidate (MPH) and non-stimulants such as atomoxetine are effective medications for the treatment of ADHD. However, about 30{\%} of patients do not respond to these medications. Pharmacological treatment for ADHD, although highly effective, is associated with marked variabilities in clinical response, optimal dosage needed and tolerability. This article provides an overview of up-to-date knowledge regarding the clinical and neurobiological factors which contribute to and help predict treatment-refractory ADHD. Pharmacogenetic, pharmacogenomics and neuroimaging studies are still controversial with respect to determining the associations between response to medication and genetic factors, thereby resulting in hypotheses that differences in the genetic factors and neuroimaging findings contribute to treatment outcome. Much research on the potential role of genotype in pharmacological effects has focused on the catecholaminergic gene related to executive functions. Many neuroimaging studies have also reported a relationship between treatment response and common patterns of brain structure or activity according to various genetic polymorphisms. When children, adolescents and adults with ADHD do not respond to MPH, we should consider additional pharmacological options, including other classes of psychostimulants, the nonstimulant atomoxetine, bupropion, tricyclic antidepressant, clonidine, guanfacine and lisdexamphetamine. Prudent choice of an appropriate medication and active engagement of children, parents, and teachers in daily management may help to ensure long-term adherence. Therefore, additional research might help to optimize the treatment of children, adolescents and adults with ADHD and to find new options for the treatment of patients who do not respond to stimulants and the other medications. Because these findings should be interpreted cautiously, further studies are needed to elucidate these issues more clearly.",
keywords = "Atomoxetine, Attention deficit hyperactivity disorder, Methylphenidate, Neuroimaging, Pharmacogenetics, Treatment response",
author = "Shim, {Se Hoon} and Yoon, {Hee jung} and Jeongjae Bak and Hahn, {Sang Woo} and Kim, {Yong Ku}",
year = "2016",
month = "2",
day = "2",
doi = "10.1016/j.pnpbp.2016.04.007",
language = "English",
volume = "70",
pages = "237--244",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Clinical and neurobiological factors in the management of treatment refractory attention-deficit hyperactivity disorder

AU - Shim, Se Hoon

AU - Yoon, Hee jung

AU - Bak, Jeongjae

AU - Hahn, Sang Woo

AU - Kim, Yong Ku

PY - 2016/2/2

Y1 - 2016/2/2

N2 - Attention-deficit/hyperactivity disorder (ADHD) is a highly prevalent mental disorder of childhood, which often continues into adolescence and adulthood. Stimulants such as methylphenidate (MPH) and non-stimulants such as atomoxetine are effective medications for the treatment of ADHD. However, about 30% of patients do not respond to these medications. Pharmacological treatment for ADHD, although highly effective, is associated with marked variabilities in clinical response, optimal dosage needed and tolerability. This article provides an overview of up-to-date knowledge regarding the clinical and neurobiological factors which contribute to and help predict treatment-refractory ADHD. Pharmacogenetic, pharmacogenomics and neuroimaging studies are still controversial with respect to determining the associations between response to medication and genetic factors, thereby resulting in hypotheses that differences in the genetic factors and neuroimaging findings contribute to treatment outcome. Much research on the potential role of genotype in pharmacological effects has focused on the catecholaminergic gene related to executive functions. Many neuroimaging studies have also reported a relationship between treatment response and common patterns of brain structure or activity according to various genetic polymorphisms. When children, adolescents and adults with ADHD do not respond to MPH, we should consider additional pharmacological options, including other classes of psychostimulants, the nonstimulant atomoxetine, bupropion, tricyclic antidepressant, clonidine, guanfacine and lisdexamphetamine. Prudent choice of an appropriate medication and active engagement of children, parents, and teachers in daily management may help to ensure long-term adherence. Therefore, additional research might help to optimize the treatment of children, adolescents and adults with ADHD and to find new options for the treatment of patients who do not respond to stimulants and the other medications. Because these findings should be interpreted cautiously, further studies are needed to elucidate these issues more clearly.

AB - Attention-deficit/hyperactivity disorder (ADHD) is a highly prevalent mental disorder of childhood, which often continues into adolescence and adulthood. Stimulants such as methylphenidate (MPH) and non-stimulants such as atomoxetine are effective medications for the treatment of ADHD. However, about 30% of patients do not respond to these medications. Pharmacological treatment for ADHD, although highly effective, is associated with marked variabilities in clinical response, optimal dosage needed and tolerability. This article provides an overview of up-to-date knowledge regarding the clinical and neurobiological factors which contribute to and help predict treatment-refractory ADHD. Pharmacogenetic, pharmacogenomics and neuroimaging studies are still controversial with respect to determining the associations between response to medication and genetic factors, thereby resulting in hypotheses that differences in the genetic factors and neuroimaging findings contribute to treatment outcome. Much research on the potential role of genotype in pharmacological effects has focused on the catecholaminergic gene related to executive functions. Many neuroimaging studies have also reported a relationship between treatment response and common patterns of brain structure or activity according to various genetic polymorphisms. When children, adolescents and adults with ADHD do not respond to MPH, we should consider additional pharmacological options, including other classes of psychostimulants, the nonstimulant atomoxetine, bupropion, tricyclic antidepressant, clonidine, guanfacine and lisdexamphetamine. Prudent choice of an appropriate medication and active engagement of children, parents, and teachers in daily management may help to ensure long-term adherence. Therefore, additional research might help to optimize the treatment of children, adolescents and adults with ADHD and to find new options for the treatment of patients who do not respond to stimulants and the other medications. Because these findings should be interpreted cautiously, further studies are needed to elucidate these issues more clearly.

KW - Atomoxetine

KW - Attention deficit hyperactivity disorder

KW - Methylphenidate

KW - Neuroimaging

KW - Pharmacogenetics

KW - Treatment response

UR - http://www.scopus.com/inward/record.url?scp=84975150238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975150238&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2016.04.007

DO - 10.1016/j.pnpbp.2016.04.007

M3 - Article

C2 - 27103462

AN - SCOPUS:84975150238

VL - 70

SP - 237

EP - 244

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

ER -